GOVX Share Price Performance
US$0
-22.50 (-100.00%)
Price US$0
Fair ValueUS$77.50
Share Pricen/a
Narrative Update • May 25
GeoVax Labs, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
GOVX Community Narratives
AN
Fair Value
·Fair Value US$77.5 98.5% undervalued intrinsic discount
Regulatory Advances And Pipeline Expansion Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
AN
Fair Value
·Fair Value US$6 80.5% undervalued intrinsic discount
Mpox And Smallpox Trial And Funding Setbacks Will Eventually Support A Stronger Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$14 91.6% undervalued intrinsic discount
Diversified Vaccine And Cancer Therapy Platform Will Transform Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Advances And Pipeline Expansion Will Unlock Future Potential
GeoVax Labs could get some of its vaccines into the market faster than usual, helped by regulators and growing interest from governments in securing local vaccine supply. But it’s still burning cash and faces long development timelines and tough competition, so the upside depends on landing key partnerships and getting trials over the line.Read more
AN
US$77.5
98.5% undervalued intrinsic discount
Fair Value
Profit Margin
34.13%
Future PE
17.11x
Price in 2029
US$89.68
Mpox And Smallpox Trial And Funding Setbacks Will Eventually Support A Stronger Outlook
Catalysts About GeoVax Labs GeoVax Labs develops vaccines and cancer therapies focused on unmet medical needs in infectious disease and oncology. What are the underlying business or industry changes driving this perspective?Read more
AN
US$6
80.5% undervalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
5.3x
Price in 2029
US$7.35
Diversified Vaccine And Cancer Therapy Platform Will Transform Long Term Earnings Potential
Catalysts About GeoVax Labs GeoVax Labs develops novel cancer therapies and infectious disease vaccines targeting high unmet medical needs worldwide. What are the underlying business or industry changes driving this perspective?Read more
AN
US$14
91.6% undervalued intrinsic discount
Fair Value
Profit Margin
73.47%
Future PE
1.05x
Price in 2028
US$17.17
Trending Discussion
Recently Updated Narratives
AN
GOVX: Mpox And Ebola Vaccine Portfolio Will Drive Future Upside
Fair Value: US$77.5 98.5% undervalued intrinsic discount
21 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Mpox And Smallpox Trial And Funding Setbacks Will Eventually Support A Stronger Outlook
Fair Value: US$6 80.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Diversified Vaccine And Cancer Therapy Platform Will Transform Long Term Earnings Potential
Fair Value: US$14 91.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GeoVax Labs, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -7.39
- -2,026.24%
- -2,507.27%
- 0%
About GOVX
- Founded
- 1988
- Employees
- 19
- CEO
- WebsiteView website
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
